Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to elucidate whether night-time dosing of mirebegron can improve nocturia, compared with daytime dosing of mirabegron.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Far Eastern Memorial Hospital
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• OAB symptoms for at least one month

• >20 years

Exclusion Criteria:

• Allergy to mirabegron, urinary tract infections, unstable hypertension